Pages that link to "Q36099124"

The following pages link to Molecular determinants of antiviral potency of paramyxovirus entry inhibitors (Q36099124):

Displaying 44 items.

• Modes of paramyxovirus fusion: a Henipavirus perspective (Q24604089) (← links)
• Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics (Q27002511) (← links)
• Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus (Q27430064) (← links)
• A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity (Q28729918) (← links)
• Inhibition of Henipavirus infection by RNA interference (Q31170002) (← links)
• Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. (Q33415278) (← links)
• Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening. (Q33442557) (← links)
• Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro (Q33514948) (← links)
• Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines (Q33657931) (← links)
• Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry (Q33741962) (← links)
• Viral entry inhibitors targeted to the membrane site of action. (Q33990602) (← links)
• Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection (Q34594547) (← links)
• Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery (Q35515383) (← links)
• Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus (Q35604856) (← links)
• Hendra and Nipah Infection: Pathology, Models and Potential Therapies (Q35658146) (← links)
• Emerging paramyxoviruses: molecular mechanisms and antiviral strategies (Q35658152) (← links)
• Features of Circulating Parainfluenza Virus Required for Growth in Human Airway. (Q36727644) (← links)
• Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. (Q37121907) (← links)
• Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. (Q37232820) (← links)
• Kinetic dependence of paramyxovirus entry inhibition. (Q37232863) (← links)
• Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation (Q37252586) (← links)
• Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. (Q37412509) (← links)
• Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors (Q37446872) (← links)
• Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. (Q37715076) (← links)
• Viral channel forming proteins - modeling the target (Q37764974) (← links)
• Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes (Q37779934) (← links)
• Henipavirus Membrane Fusion and Viral Entry (Q37994632) (← links)
• Extolling the benefits of molecular therapeutic lipidation (Q38114781) (← links)
• Henipavirus pathogenesis and antiviral approaches (Q38337204) (← links)
• Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function (Q38632078) (← links)
• Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein (Q39462591) (← links)
• Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action (Q39528697) (← links)
• Effects of macromolecular crowding on the inhibition of virus assembly and virus-cell receptor recognition. (Q39600262) (← links)
• A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade (Q39697289) (← links)
• Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins. (Q40039979) (← links)
• Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses (Q40109981) (← links)
• A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry (Q40376100) (← links)
• Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection. (Q45324172) (← links)
• Biophysical Properties and Antiviral Activities of Measles Fusion Protein Derived Peptide Conjugated with 25-Hydroxycholesterol. (Q47582990) (← links)
• Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates. (Q51783167) (← links)
• Therapeutic potential of targeting the Eph/ephrin signaling complex (Q57812327) (← links)
• Analysis of a subacute sclerosing panencephalitis (SSPE) Genotype B3 virus from the 2009/10 South African measles epidemic shows hyperfusogenic F proteins contribute to measles virus infection in the brain (Q59349680) (← links)
• Predicting and designing therapeutics against the Nipah virus (Q91917203) (← links)
• Peptide inhibitors of tembusu virus infection derived from the envelope protein (Q95836309) (← links)